APS Stock Overview
A clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Aptose Biosciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.55 |
| 52 Week High | CA$4.56 |
| 52 Week Low | CA$0.46 |
| Beta | 1.36 |
| 11 Month Change | 3.77% |
| 3 Month Change | -46.08% |
| 1 Year Change | -85.37% |
| 33 Year Change | -98.67% |
| 5 Year Change | -98.69% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Here's Why We're Watching Aptose Biosciences' (TSE:APS) Cash Burn Situation
Mar 26
We're Keeping An Eye On Aptose Biosciences' (TSE:APS) Cash Burn Rate
Dec 08We're Keeping An Eye On Aptose Biosciences' (TSE:APS) Cash Burn Rate
Aug 05We Think Aptose Biosciences (TSE:APS) Needs To Drive Business Growth Carefully
Apr 02Companies Like Aptose Biosciences (TSE:APS) Are In A Position To Invest In Growth
Sep 30Aptose Biosciences Inc. (TSE:APS) Insiders Have Been Selling
Feb 07
Is Aptose Biosciences Inc.'s (TSE:APS) Shareholder Ownership Skewed Towards Insiders?
Jan 03We're Not Very Worried About Aptose Biosciences' (TSE:APS) Cash Burn Rate
Nov 29Jotin Marango Is The Senior VP & Chief Business Officer of Aptose Biosciences Inc. (TSE:APS) And They Just Sold 26% Of Their Shares
Jul 11Aptose Biosciences Inc. (TSE:APS) Insiders Have Been Selling
Jun 27Shareholder Returns
| APS | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 1.9% | -2.7% | 1.1% |
| 1Y | -85.4% | -40.5% | 20.6% |
Return vs Industry: APS underperformed the Canadian Biotechs industry which returned -40.5% over the past year.
Return vs Market: APS underperformed the Canadian Market which returned 20.6% over the past year.
Price Volatility
| APS volatility | |
|---|---|
| APS Average Weekly Movement | 11.8% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.0% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: APS's share price has been volatile over the past 3 months.
Volatility Over Time: APS's weekly volatility (12%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 36 | William Rice | www.aptose.com |
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. The company’s clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin’s lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd.
Aptose Biosciences Inc. Fundamentals Summary
| APS fundamental statistics | |
|---|---|
| Market cap | CA$9.96m |
| Earnings (TTM) | -CA$54.28m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs APS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$40.29m |
| Earnings | -US$40.29m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.23 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did APS perform over the long term?
See historical performance and comparison